The DOI matches its Crossref record; 151 of the 151 references it cites were found in a registry or an index.
Triple Negative Breast Cancer Treatment Options and Limitations: Future Outlook
Open accessAbstract
Triple negative breast cancer (TNBC) has a negative expression of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptors (HER2). The survival rate for TNBC is generally worse than other breast cancer subtypes. TNBC treatment has made significant advances, but certain limitations remain. Treatment for TNBC can be challenging since the disease has various molecular subtypes. A variety of treatment options are available, such as chemotherapy, immunotherapy, radiotherapy, and surgery. Chemotherapy is the most common of these options. TNBC is generally treated with systemic chemotherapy using drugs such as anthracyclines and taxanes in neoadjuvant or adjuvant settings. Developing resistance to anticancer drugs and off-target toxicity are the primary hindrances to chemotherapeutic solutions for cancer. It is imperative that researchers, clinicians, and pharmaceutical companies work together to develop effective treatment options for TNBC. Several studies have suggested nanotechnology as a potential solution to the problem of suboptimal TNBC treatment. In this review, we summarized possible treatment options for TNBC, including chemotherapy, immunotherapy, targeted therapy, combination therapy, and nanoparticle-based therapy, and some solutions for the treatment of TNBC in the future. Moreover, we gave general information about TNBC in terms of its characteristics and aggressiveness.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21660 · Cited by 108,699
Matsumura, Y., & Maeda, H. (1986) · PubMed · Cited by 6,781
Nielsen, T. O., Hsu, F. D., Jensen, K., Cheang, M., Karaca, G., Hu, Z., Hernandez-Boussard, T., Livasy, C., Cowan, D., Dressler, L., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0220 · Cited by 2,663
Triple-negative breast cancer molecular subtyping and treatment progress
Yin, L., Duan, J.-J., Bian, X.-W., & Yu, S.-C. (2020) · Breast Cancer Research · doi:10.1186/s13058-020-01296-5 · Cited by 2,452
Denkert, C., von Minckwitz, G., Darb-Esfahani, S., Lederer, B., Heppner, B. I., Weber, K. E., Budczies, J., Huober, J., Klauschen, F., Furlanetto, J., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30904-x · Cited by 2,157
Bauer, K. R., Brown, M., Cress, R. D., Parise, C. A., & Caggiano, V. (2007) · Cancer · doi:10.1002/cncr.22618 · Cited by 2,067
Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy
Rouzier, R., Perou, C. M., Symmans, W. F., Ibrahim, N., Cristofanilli, M., Anderson, K., Hess, K. R., Stec, J., Ayers, M., Wagner, P., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2421 · Cited by 1,891
Cisplatin: The first metal based anticancer drug
Ghosh, S. (2019) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2019.102925 · Cited by 1,751
Lord, C. J., & Ashworth, A. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2015.21 · Cited by 1,257
Attia, M. F., Anton, N., Wallyn, J., Omran, Z., & Vandamme, T. F. (2019) · Journal of Pharmacy and Pharmacology · doi:10.1111/jphp.13098 · Cited by 1,085
Haffty, B. G., Yang, Q., Reiss, M., Kearney, T., Higgins, S. A., Weidhaas, J., Harris, L., Hait, W., & Toppmeyer, D. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5664 · Cited by 1,084
PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside
Alzahrani, A. S. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.07.009 · Cited by 1,054
Recent advances in therapeutic strategies for triple-negative breast cancer
Li, Y., Zhang, H., Merkher, Y., Chen, L., Liu, N., Leonov, S., & Chen, Y. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01341-0 · Cited by 956
Carboplatin in BRCA1/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial
Tutt, A., Tovey, H., Cheang, M. C. U., Kernaghan, S., Kilburn, L., Gazinska, P., Owen, J., Abraham, J., Barrett, S., Barrett-Lee, P., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0009-7 · Cited by 912
Sacituzumab govitecan-hziy in refractory metastatic triple-negative breast cancer
Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1814213 · Cited by 874
Nedeljković, M., & Damjanović, A. (2019) · Cells · doi:10.3390/cells8090957 · Cited by 870
Gold Nanoparticles for the Improved Anticancer Drug Delivery of the Active Component of Oxaliplatin
Brown, S. D., Nativo, P., Smith, J.-A., Stirling, D., Edwards, P. R., Venugopal, B., Flint, D. J., Plumb, J. A., Graham, D., & Wheate, N. J. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908117a · Cited by 865
Adams, S., Schmid, P., Rugo, H. S., Winer, E. P., Loirat, D., Awada, A., Cescon, D. W., Iwata, H., Campone, M., Nanda, R., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdy517 · Cited by 807
Role of epidermal growth factor receptor in breast cancer
Masuda, H., Zhang, D., Bartholomeusz, C., Doihara, H., Hortobagyi, G. N., & Ueno, N. T. (2012) · Breast Cancer Research and Treatment · doi:10.1007/s10549-012-2289-9 · Cited by 806
Antibody–Drug Conjugates: A Comprehensive Review
Khongorzul, P., Ling, C. J., Khan, F. U., Ihsan, A. U., & Zhang, J. (2020) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-19-0582 · Cited by 787
Loibl, S., O'Shaughnessy, J., Untch, M., Sikov, W. M., Rugo, H. S., McKee, M. D., Huober, J., Golshan, M., von Minckwitz, G., Maag, D., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30111-6 · Cited by 768
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 695
The application of nanoparticles in cancer immunotherapy: Targeting tumor microenvironment
Yang, M., Li, J., Gu, P., & Fan, X. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2020.12.010 · Cited by 670
Natural Products as Anticancer Agents: Current Status and Future Perspectives
Naeem, A., Hu, P., Yang, M., Zhang, J., Liu, Y., Zhu, W., & Zheng, Q. (2022) · Molecules · doi:10.3390/molecules27238367 · Cited by 607
Enzalutamide for the Treatment of Androgen Receptor–Expressing Triple-Negative Breast Cancer
Traina, T. A., Miller, K., Yardley, D. A., Eakle, J., Schwartzberg, L. S., O’Shaughnessy, J., Gradishar, W., Schmid, P., Winer, E., Kelly, C., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.3495 · Cited by 530
Triple‑negative breast cancer therapy: Current and future perspectives (Review)
Won, K., & Spruck, C. (2020) · International Journal of Oncology · doi:10.3892/ijo.2020.5135 · Cited by 527
Metastatic and triple-negative breast cancer: challenges and treatment options
Al-Mahmood, S., Sapiezynski, J., Garbuzenko, O. B., & Minko, T. (2018) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-0551-3 · Cited by 524
The Use of Alternative Strategies for Enhanced Nanoparticle Delivery to Solid Tumors
Izci, M., Maksoudian, C., Manshian, B. B., & Soenen, S. J. (2021) · Chemical Reviews · doi:10.1021/acs.chemrev.0c00779 · Cited by 506
Poggio, F., Bruzzone, M., Ceppi, M., Pondé, N. F., La Valle, G., Del Mastro, L., de Azambuja, E., & Lambertini, M. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy127 · Cited by 468
The Landscape of Targeted Therapies in TNBC
Vagia, E., Mahalingam, D., & Cristofanilli, M. (2020) · Cancers · doi:10.3390/cancers12040916 · Cited by 450
Triple-Negative Breast Cancer: Risk Factors to Potential Targets
Schneider, B. P., Winer, E. P., Foulkes, W. D., Garber, J., Perou, C. M., Richardson, A., Sledge, G. W., & Carey, L. A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1208 · Cited by 437
Passive targeting of nanoparticles to cancer: A comprehensive review of the literature
BAZAK, R., HOURI, M., ACHY, S. E., HUSSEIN, W., & REFAAT, T. (2014) · Molecular and Clinical Oncology · doi:10.3892/mco.2014.356 · Cited by 435
Schmid, P., Salgado, R., Park, Y. H., Muñoz-Couselo, E., Kim, S. B., Sohn, J., Im, S.-A., Foukakis, T., Kuemmel, S., Dent, R., et al. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.01.072 · Cited by 413
Inhibit or Evade Multidrug Resistance P-Glycoprotein in Cancer Treatment: Miniperspective
Waghray, D., & Zhang, Q. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b01457 · Cited by 400
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming
Mosca, L., Ilari, A., Fazi, F., Assaraf, Y. G., & Colotti, G. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100742 · Cited by 385
The fate of chemoresistance in triple negative breast cancer (TNBC)
O’Reilly, E. A., Gubbins, L., Sharma, S., Tully, R., Guang, M. H. Z., Weiner-Gorzel, K., McCaffrey, J., Harrison, M., Furlong, F., Kell, M., et al. (2015) · BBA Clinical · doi:10.1016/j.bbacli.2015.03.003 · Cited by 377
Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer
Corkery, B., Crown, J., Clynes, M., & O'Donovan, N. (2009) · Annals of Oncology · doi:10.1093/annonc/mdn710 · Cited by 348
Triple-Negative Breast Cancer: A Review of Conventional and Advanced Therapeutic Strategies
Medina, M. A., Oza, G., Sharma, A., Arriaga, L. G., Hernández Hernández, J. M., Rotello, V. M., & Ramirez, J. T. (2020) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph17062078 · Cited by 333
Gupta, G. K., Collier, A. L., Lee, D., Hoefer, R. A., Zheleva, V., Siewertsz van Reesema, L. L., Tang-Tan, A. M., Guye, M. L., Chang, D. Z., Winston, J. S., et al. (2020) · Cancers · doi:10.3390/cancers12092392 · Cited by 331
Strategies to improve the EPR effect: A mechanistic perspective and clinical translation
Ikeda-Imafuku, M., Wang, L. L.-W., Rodrigues, D., Shaha, S., Zhao, Z., & Mitragotri, S. (2022) · Journal of Controlled Release · doi:10.1016/j.jconrel.2022.03.043 · Cited by 330
Pembrolizumab and atezolizumab in triple-negative breast cancer
Kwapisz, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02736-z · Cited by 271
Triple negative breast cancer: A thorough review of biomarkers
da Silva, J. L., Cardoso Nunes, N. C., Izetti, P., de Mesquita, G. G., & de Melo, A. C. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2019.102855 · Cited by 270
Genetic Markers in Triple-Negative Breast Cancer
Sporikova, Z., Koudelakova, V., Trojanec, R., & Hajduch, M. (2018) · Clinical Breast Cancer · doi:10.1016/j.clbc.2018.07.023 · Cited by 262
Drug Delivery Strategies for Platinum-Based Chemotherapy
Browning, R. J., Reardon, P. J. T., Parhizkar, M., Pedley, R. B., Edirisinghe, M., Knowles, J. C., & Stride, E. (2017) · ACS Nano · doi:10.1021/acsnano.7b04092 · Cited by 247
Khan, M. A., Jain, V. K., Rizwanullah, M., Ahmad, J., & Jain, K. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.09.001 · Cited by 246
Ibrahim, E. M., Al-Foheidi, M. E., Al-Mansour, M. M., & Kazkaz, G. A. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3185-2 · Cited by 245
Vaz-Luis, I., Ottesen, R. A., Hughes, M. E., Mamet, R., Burstein, H. J., Edge, S. B., Gonzalez-Angulo, A. M., Moy, B., Rugo, H. S., Theriault, R. L., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.1608 · Cited by 244
Barton, V. N., D'Amato, N. C., Gordon, M. A., Lind, H. T., Spoelstra, N. S., Babbs, B. L., Heinz, R. E., Elias, A., Jedlicka, P., Jacobsen, B. M., et al. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0926 · Cited by 239
Triple-negative breast cancer: promising prognostic biomarkers currently in development
Sukumar, J., Gast, K., Quiroga, D., Lustberg, M., & Williams, N. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1840984 · Cited by 239
Ejigah, V., Owoseni, O., Bataille-Backer, P., Ogundipe, O. D., Fisusi, F. A., & Adesina, S. K. (2022) · Polymers · doi:10.3390/polym14132601 · Cited by 234
Wang, X., Wang, S.-S., Huang, H., Cai, L., Zhao, L., Peng, R.-J., Lin, Y., Tang, J., Zeng, J., Zhang, L.-H., et al. (2021) · JAMA · doi:10.1001/jama.2020.23370 · Cited by 229
Olaparib monotherapy as primary treatment in unselected triple negative breast cancer
Eikesdal, H. P., Yndestad, S., Elzawahry, A., Llop-Guevara, A., Gilje, B., Blix, E. S., Espelid, H., Lundgren, S., Geisler, J., Vagstad, G., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2020.11.009 · Cited by 219
Yu, K.-D., Ye, F.-G., He, M., Fan, L., Ma, D., Mo, M., Wu, J., Liu, G.-Y., Di, G.-H., Zeng, X.-H., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.2965 · Cited by 213
Triple Negative Breast Cancer: Updates on Classification and Treatment in 2021
Bou Zerdan, M., Ghorayeb, T., Saliba, F., Allam, S., Bou Zerdan, M., Yaghi, M., Bilani, N., Jaafar, R., & Nahleh, Z. (2022) · Cancers · doi:10.3390/cancers14051253 · Cited by 208
Therapeutic targets of triple‐negative breast cancer: a review
Jamdade, V. S., Sethi, N., Mundhe, N. A., Kumar, P., Lahkar, M., & Sinha, N. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13211 · Cited by 205
Wan, X., Beaudoin, J. J., Vinod, N., Min, Y., Makita, N., Bludau, H., Jordan, R., Wang, A., Sokolsky, M., & Kabanov, A. V. (2019) · Biomaterials · doi:10.1016/j.biomaterials.2018.10.032 · Cited by 201 · cited 1×
“where a A2780/CisR-resistant xenograft tumor and LCC-6MDR multidrug-resistant breast cancer orthotopic model demonstrated superior antitumor activity with co-loaded PTX/Cisplatin drug micelles compared with single drug micelles [128].”
BackgroundPlasilova, M. L., Hayse, B., Killelea, B. K., Horowitz, N. R., Chagpar, A. B., & Lannin, D. R. (2016) · Medicine · doi:10.1097/md.0000000000004614 · Cited by 201
Nanotechnology: A Promising Approach for Cancer Diagnosis, Therapeutics and Theragnosis
Dessale, M., Mengistu, G., & Mengist, H. M. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s378074 · Cited by 191
Triple Negative Breast Cancer: A Review of Present and Future Diagnostic Modalities
Dass, S. A., Tan, K. L., Rajan, R. S., Mokhtar, N. F., Adzemi, E. R. M., Rahman, W. F. W. A., Din, T. A. D. A. T., & Balakrishnan, V. (2021) · Medicina · doi:10.3390/medicina57010062 · Cited by 188
Liu, J., Liu, Q., Li, Y., Li, Q., Su, F., Yao, H., Su, S., Wang, Q., Jin, L., Wang, Y., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000696 · Cited by 183
The Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
O'Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2641 · Cited by 182
Prakash, O., Hossain, F. M., Danos, D., Lassak, A., Scribner, R. A., & Miele, L. (2020) · Frontiers in Public Health · doi:10.3389/fpubh.2020.576964 · Cited by 178
Triple-negative breast cancer: current perspective on the evolving therapeutic landscape
Mehanna, J., Haddad, F. G., Eid, R., Lambertini, M., & Kourie, H. R. (2019) · International Journal of Women's Health · doi:10.2147/ijwh.s178349 · Cited by 172
The Evolution of Triple-Negative Breast Cancer: From Biology to Novel Therapeutics
Anders, C. K., Abramson, V. G., Tan, T. J., & Dent, R. A. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_159135 · Cited by 172
Park, J. H., Ahn, J. H., & Kim, S. (2018) · ESMO Open · doi:10.1136/esmoopen-2018-000357 · Cited by 170
Role of the androgen receptor in triple-negative breast cancer.
Rampurwala, M. M., Wisinski, K. B., & O'Regan, R. M. (2016) · PubMed · Cited by 163
Targeting Breast Cancer Stem Cells to Overcome Treatment Resistance
Palomeras, S., Ruiz-Martínez, S., & Puig, T. (2018) · Molecules · doi:10.3390/molecules23092193 · Cited by 163
Cho, B., Han, Y., Lian, M., Colditz, G. A., Weber, J. D., Ma, C. X., & Liu, Y. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2021.1254 · Cited by 161
Behera, A., & Padhi, S. (2020) · Environmental Chemistry Letters · doi:10.1007/s10311-020-01022-9 · Cited by 159
Pandy, J. G. P., Balolong-Garcia, J. C., Cruz-Ordinario, M. V. B., & Que, F. V. (2019) · BMC Cancer · doi:10.1186/s12885-019-6253-5 · Cited by 157
Overview of recent advances in metastatic triple negative breast cancer
O'Reilly, D., AlSendi, M., & Kelly, C. M. (2021) · World Journal of Clinical Oncology · doi:10.5306/wjco.v12.i3.164 · Cited by 157
Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer
Luo, C., Wang, P., He, S., Zhu, J., Shi, Y., & Wang, J. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.919072 · Cited by 157
Treatment Strategies Against Triple-Negative Breast Cancer: An Updated Review
Maqbool, M., Bekele, F., & Fekadu, G. (2022) · Breast Cancer Targets and Therapy · doi:10.2147/bctt.s348060 · Cited by 154
Yang, R., Li, Y., Wang, H., Qin, T., Yin, X., & Ma, X. (2022) · Molecular Biomedicine · doi:10.1186/s43556-022-00071-6 · Cited by 154
PARP Inhibitors in the Treatment of Triple-Negative Breast Cancer
Geenen, J. J. J., Linn, S. C., Beijnen, J. H., & Schellens, J. H. M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-017-0587-4 · Cited by 143
Kutty, R. V., & Feng, S. (2013) · Biomaterials · doi:10.1016/j.biomaterials.2013.09.043 · Cited by 142
Yardley, D. A., Coleman, R., Conte, P., Cortés, J., Brufsky, A., Shtivelband, M. I., Young, R. R., Bengala, C., Ali, H. Y., Eakel, J., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy201 · Cited by 140
Yagata, H., Kajiura, Y., & Yamauchi, H. (2011) · Breast Cancer · doi:10.1007/s12282-011-0254-9 · Cited by 137
Biomarkers in Triple-Negative Breast Cancer: State-of-the-Art and Future Perspectives
Cocco, S., Piezzo, M., Calabrese, A., Cianniello, D., Caputo, R., Lauro, V. D., Fusco, G., Gioia, G. D., Licenziato, M., & Laurentiis, M. D. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21134579 · Cited by 137
Sharma, P., López‐Tarruella, S., García-Sáenz, J. Á., Khan, Q. J., Gómez, H., Prat, A., Moreno, F., Jerez-Gilarranz, Y., Barnadas, A., Picornell, A. C., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0585 · Cited by 133
Mizrahi, D., Park, S. B., Li, T., Timmins, H. C., Trinh, T., Au, K., Battaglini, E., Wyld, D., Henderson, R. D., Grimison, P., et al. (2021) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.36695 · Cited by 128
Liao, M., Zhang, J. C., Wang, G., Wang, L., Liu, J., Ouyang, L., & Liu, B. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01180 · Cited by 128
Immunotherapy in triple-negative breast cancer
Katz, H., & Alsharedi, M. F. (2017) · Medical Oncology · doi:10.1007/s12032-017-1071-6 · Cited by 122
The Role of the Androgen Receptor in Triple-Negative Breast Cancer
Shah, P. D., Gucalp, A., & Traina, T. A. (2013) · Women s Health · doi:10.2217/whe.13.33 · Cited by 121
Barchiesi, G., Roberto, M., Verrico, M., Vici, P., Tomao, F., & Tomao, F. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.769280 · Cited by 120
Atezolizumab for the treatment of triple-negative breast cancer
Heimes, A.-S., & Schmidt, M. (2018) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2019.1552255 · Cited by 116
Jusu, S. M., Obayemi, J. D., Salifu, A. A., Nwazojie, C. C., Uzonwanne, V., Odusanya, O. S., & Soboyejo, W. O. (2020) · Scientific Reports · doi:10.1038/s41598-020-71129-0 · Cited by 112
Nanoparticles for Biomedical Applications
Child, H. (2019) · Elsevier eBooks · doi:10.1016/c2017-0-04750-x · Cited by 111
Wathoni, N., Puluhulawa, L. E., Joni, I. M., Muchtaridi, M., Mohammed, A. F. A., Elamin, K. M., Milanda, T., & Gozali, D. (2022) · Drug Delivery · doi:10.1080/10717544.2022.2120566 · Cited by 111
DNA Nanostructures Carrying Stoichiometrically Definable Antibodies
Setyawati, M. I., Kutty, R. V., & Leong, D. T. (2016) · Small · doi:10.1002/smll.201601669 · Cited by 109
The Landmark Series: Neoadjuvant Chemotherapy for Triple-Negative and HER2-Positive Breast Cancer
Leon-Ferre, R. A., Hieken, T. J., & Boughey, J. C. (2021) · Annals of Surgical Oncology · doi:10.1245/s10434-020-09480-9 · Cited by 109
Therapies for triple negative breast cancer
Andreopoulou, E., Schweber, S. J., Sparano, J. A., & McDaid, H. M. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1032246 · Cited by 103
The Management of Early-Stage and Metastatic Triple-Negative Breast Cancer
Anders, C. K., Zagar, T. M., & Carey, L. (2013) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2013.05.003 · Cited by 101
Surface Modification of Nanoparticles for Targeted Drug Delivery
Pathak, Y. V. (2019) · Springer eBooks · doi:10.1007/978-3-030-06115-9 · Cited by 101
Sheng, Y., Bi, X., Yang, L. F., Shan-guang, W., Yu, Y., Jiang, B., Zhang, A., Lan, K., & Duan, S. (2019) · Journal of Biomedical Nanotechnology · doi:10.1166/jbn.2019.2751 · Cited by 98
Wu, S., Xu, Y., Chen, L., Fan, L., Ma, X.-Y., Zhao, S., Song, X.-Q., Hu, X., Yang, W.-T., Chai, W.-J., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01536-6 · Cited by 98
Lv, Y., Ma, X., Du, Y., & Feng, J. (2021) · OncoTargets and Therapy · doi:10.2147/ott.s293685 · Cited by 96
EGFR Promotes the Development of Triple Negative Breast Cancer Through JAK/STAT3 Signaling
Song, X. Y., Liu, Z., & Yu, Z. (2020) · Cancer Management and Research · doi:10.2147/cmar.s225376 · Cited by 95
Reddy, L. H., & Bazile, D. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.10.007 · Cited by 91
A review of current progress in triple-negative breast cancer therapy
Shen, M., Pan, H., Chen, Y., Xu, Y. H., Yang, W., & Wu, Z. (2020) · Open Medicine · doi:10.1515/med-2020-0138 · Cited by 89
Rigiracciolo, D. C., Nohata, N., Lappano, R., Cirillo, F., Talia, M., Scordamaglia, D., Gutkind, J. S., & Maggiolini, M. (2020) · Cells · doi:10.3390/cells9041010 · Cited by 88
“Targeting Design” of Nanoparticles in Tumor Therapy
Yang, T., Zhai, J., Hu, D., Yang, R., Wang, G., Li, Y., & Liang, G. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14091919 · Cited by 88
Novel therapeutic strategies in the treatment of triple-negative breast cancer
Oualla, K., El‐Zawahry, H. M., Arun, B., Reuben, J. M., Woodward, W. A., El-Din, H. G., Lim, B., Mellas, N., Ueno, N. T., & Fouad, T. M. (2017) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834017711380 · Cited by 84
Adjuvant Anthracyclines in Breast Cancer: What Is Their Role?
Shah, A. N., & Gradishar, W. J. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0672 · Cited by 84
Bioactive nanotherapeutic trends to combat triple negative breast cancer
Chowdhury, P., Ghosh, U., Samanta, K., Jaggi, M., Chauhan, S. C., & Yallapu, M. M. (2021) · Bioactive Materials · doi:10.1016/j.bioactmat.2021.02.037 · Cited by 84
New Perspectives for Resistance to PARP Inhibitors in Triple-Negative Breast Cancer
Han, Y., Yu, X., Li, S., Tian, Y. E., & Liu, C. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.578095 · Cited by 77
Demeule, M., Charfi, C., Currie, J.-C., Larocque, A., Zgheib, A., Kozelko, S., Béliveau, R., Marsolais, C., & Annabi, B. (2021) · Cancer Science · doi:10.1111/cas.15086 · Cited by 76
BRD4 inhibition suppresses PD-L1 expression in triple-negative breast cancer
Jing, X., Shao, S. H., Zhang, Y., Luo, A., Zhao, L., Zhang, L., Gu, S., & Zhao, X. (2020) · Experimental Cell Research · doi:10.1016/j.yexcr.2020.112034 · Cited by 75
Miller‐Kleinhenz, J. M., Bozeman, E. N., & Yang, L. P. H. (2015) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1343 · Cited by 74
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
Optimal Systemic Treatment for Early Triple-Negative Breast Cancer
Furlanetto, J., & Loibl, S. (2020) · Breast Care · doi:10.1159/000508759 · Cited by 72
Therapeutic Advances in Oncology
Liu, J., Pandya, P., & Afshar, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22042008 · Cited by 71
Fancellu, A., Houssami, N., Sanna, V., Porcu, A., Ninniri, C., & Marinovich, M. L. (2021) · British journal of surgery · doi:10.1093/bjs/znab145 · Cited by 63
Coussy, F., Lavigne, M., de Koning, L., Botty, R. E., Némati, F., Naguez, A., Bataillon, G., Ouine, B., Dahmani, A., Montaudon, É., et al. (2020) · Theranostics · doi:10.7150/thno.36182 · Cited by 62
Chen, Q.-X., Wang, X.-X., Lin, P.-Y., Zhang, J., Li, J.-J., Song, C.-G., & Shao, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.13976 · Cited by 56
Chan, J. J., Tan, T. J., & Dent, R. A. (2019) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835919880429 · Cited by 56
FZD5 contributes to TNBC proliferation, DNA damage repair and stemness
Sun, Y., Wang, Z., Lei, N., Dong, D. F., Wang, W., & Zhao, C. (2020) · Cell Death and Disease · doi:10.1038/s41419-020-03282-3 · Cited by 56
Darvishi, B., Farahmand, L., & Majidzadeh‐A, K. (2017) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2017.03.007 · Cited by 53
Enhanced sensitivity to cisplatin and gemcitabine in Brca1-deficient murine mammary epithelial cells
Alli, E., Sharma, V. B., Hartman, A., Lin, P. S., McPherson, L. A., & Ford, J. M. (2011) · BMC Pharmacology · doi:10.1186/1471-2210-11-7 · Cited by 52
Mamot, C., Ritschard, R., WICKI, A. N., Küng, W., Schuller, J. C., Herrmann, R., & Rochlitz, C. F. (2012) · Journal of drug targeting · doi:10.3109/1061186x.2012.680960 · Cited by 52
Triple‐negative breast cancer—Role of immunology: A systemic review
Öner, G., Altıntaş, S., Cantürk, Z., Tjalma, W. A. A., Verhoeven, Y., Berckelaer, C. V., Berneman, Z. N., Peeters, M., Pauwels, P., & van Dam, P. A. (2019) · The Breast Journal · doi:10.1111/tbj.13696 · Cited by 52
BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers
Blanchard, Z., Paul, B. T., Craft, B. S., & ElShamy, W. M. (2015) · Breast Cancer Research · doi:10.1186/s13058-014-0512-9 · Cited by 51
Update on systemic treatment in early triple negative breast cancer
Abad, M. N., Fariñas, S. C., de Mena, M. L., Brémond, M., González, C. G., Torres‐Martínez, S., García, J. Á., Iranzo, V., & Herrero, C. C. (2021) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920986749 · Cited by 50
PARP (Poly ADP-Ribose Polymerase) inhibitors for locally advanced or metastatic breast cancer
Taylor, A. M., Chan, D. L. H., Tio, M., Patil, S. M., Traina, T. A., Robson, M. E., & Khasraw, M. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011395.pub2 · Cited by 50
Lee, J., Cho, Y., Lee, J., & Ahn, H. J. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.02.013 · Cited by 49
Zhang, L., Mu, C., Zhang, T., Yang, D., Wang, C., Chen, Q., Tang, L., Fan, L., Liu, C., Shen, J., et al. (2021) · Journal of Nanobiotechnology · doi:10.1186/s12951-020-00758-4 · Cited by 49
O’Shaughnessy, J., Brufsky, A., Rugo, H. S., Tolaney, S. M., Punie, K., Sardesai, S. D., Hamilton, E. P., Loirat, D., Traina, T. A., Leon-Ferre, R. A., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06602-7 · Cited by 49
Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
Liu, H., Bai, L., Huang, L., Ning, N., Li, L., Li, Y., Dong, X., Du, Q., Xia, M., Chen, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003468 · Cited by 48
Ellmark, P., Mangsbo, S. M., Furebring, C., Norlén, P., & Tötterman, T. H. (2016) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-016-1909-3 · Cited by 47
Cheng, Y., Lin, L., Li, X., Lu, A., Hou, C., Wu, Q., Hu, X., Zhou, Z., Chen, Z., & Tang, F. (2021) · Cancer Cell International · doi:10.1186/s12935-020-01727-5 · Cited by 46
Bio-Inspired and Smart Nanoparticles for Triple Negative Breast Cancer Microenvironment
Shokooh, M. K., Emami, F., Jeong, J., & Yook, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13020287 · Cited by 41
Stringer-Reasor, E. M., May, J. E., Olariu, E., Caterinicchia, V., Li, Y., Chen, D., Manna, D. L. D., Rocque, G. B., Vaklavas, C., Falkson, C. I., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01408-9 · Cited by 40
Implications of Withaferin-A for triple-negative breast cancer chemoprevention
Mallipeddi, H., Thyagarajan‐Sahu, A., & Sahu, R. P. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.111124 · Cited by 40
Selective Delivery of Doxorubicin to EGFR+ Cancer Cells by Cetuximab–DNA Conjugates
Liu, T., Song, P., Märcher, A., Kjems, J., Yang, C., & Gothelf, K. V. (2018) · ChemBioChem · doi:10.1002/cbic.201800685 · Cited by 37
Role of Platinums in Triple-Negative Breast Cancer
Lynce, F. C., & Nunes, R. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01041-x · Cited by 33
New Achievements for the Treatment of Triple-Negative Breast Cancer
Catalano, A. A., Iacopetta, D., Ceramella, J., Mariconda, A., Rosano, C., Scumaci, D., Saturnino, C., Longo, P., & Sinicropi, M. S. (2022) · Applied Sciences · doi:10.3390/app12115554 · Cited by 33
Divgi, C. R., Carrasquillo, J. A., Meredith, R. F., Seo, Y., Frey, E. C., Bolch, W. E., Zimmerman, B. E., Akabani, G., Jacobson, D., Brown, B., et al. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.12.002 · Cited by 32
Emerging Therapeutic Drugs in Metastatic Triple-Negative Breast Cancer
Cipriano, É., & Mesquita, A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/11782234211002491 · Cited by 31
Eskiler, G. G., & Öztürk, M. (2021) · Cellular Signalling · doi:10.1016/j.cellsig.2021.110229 · Cited by 31
Ghebeh, H., Alsayed, A., Eiada, R., Cabangon, L., Ajarim, D. S., Suleman, K., Tulbah, A. M., & Al‐Tweigeri, T. (2021) · Scientific Reports · doi:10.1038/s41598-021-98113-6 · Cited by 30
Deep exploration of PARP inhibitors in breast cancer: monotherapy and combination therapy
Chen, Z., Wang, X., Li, X., Zhou, Y., & Chen, K. (2021) · Journal of International Medical Research · doi:10.1177/0300060521991019 · Cited by 24
Li, S., Goins, B., Hrycushko, B. A., Phillips, W. T., & Bao, A. (2012) · Molecular Pharmaceutics · doi:10.1021/mp300132f · Cited by 21
Eşim, Ö., Bakırhan, N. K., Yildirim, N., Sarper, M., Savaşer, A., Özkan, S. A., & Özkan, Y. (2020) · DARU Journal of Pharmaceutical Sciences · doi:10.1007/s40199-020-00374-5 · Cited by 19
Nisticò, N., Aloisio, A., Lupia, A., Zimbo, A. M., Mimmi, S., Maisano, D., Russo, R., Marino, F., Scalise, M., Chiarella, E., et al. (2023) · Cells · doi:10.3390/cells12071078 · Cited by 18
Medhi, H., Khumukcham, S. S., Manavathi, B., & Paik, P. (2020) · RSC Advances · doi:10.1039/d0ra04505e · Cited by 14
Misra, S., Zhang, X., Wani, N. A., Sizemore, S. T., & Ray, A. (2020) · Oncotarget · doi:10.18632/oncotarget.27485 · Cited by 13
Lembo, R. R., Manna, L., Froechlich, G., Sasso, E., Passariello, M., & Lorenzo, C. D. (2022) · Cancers · doi:10.3390/cancers14215289 · Cited by 13
Futamura, M., Oba, M. S., Masuda, N., Bando, H., Okada, M., Yamamoto, Y., Kin, T., Saeki, T., Nagashima, T., Kuwayama, T., et al. (2021) · Breast Cancer · doi:10.1007/s12282-021-01238-9 · Cited by 11
Liu, J., XIAO, Y., Wei, W., Guo, J., Liu, Y., HUANG, X.-H., Rong-xia, Z., WU, Y.-J., & Zhou, J. (2015) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2015.2489 · Cited by 10
Fisusi, F. A., Brandy, N. Z. D., Wu, J., & Akala, E. O. (2020) · PubMed · Cited by 7
Self-citationBerko, Y. A., & Akala, E. O. (2020) · Pharmaceutical Nanotechnology · doi:10.2174/2211738508666200224110410 · Cited by 2
Self-citation
Cited by
Gong, J., Cheng, D., Liu, C., Wu, S., Sun, N., Zhao, L., Li, J., Xing, Y., & Zhao, J. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202404184 · Cited by 53
Metadata
- Authors
- Obidiro, O., Battogtokh, G., & Akala, E. O.
- Venue
- Pharmaceutics
- Publisher
- MDPI AG
- Published
- 2023-06-23
- Volume
- 15
- Issue
- 7
- Pages
- 1796
- ISSN
- 1999-4923 (ISSN-L)
- OpenAlex
- W4382068653
- Cited by
- 511
- References
- 151
- FWCI
- 49.79
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.